Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. is listed today as Collegium Pharmaceutical, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2018 | $20 M | Private placement after listing | $10 to $50 million | options | SEC | |
| Mar 2015 | $50 M | No. 4 | $50 to $250 million | equity | SEC | |
| Aug 2013 | $4 M | No. 3 | $2 to $10 million | equity | SEC | |
| Feb 2012 | $22 M | No. 2 | $10 to $50 million | equity | SEC | |
| Mar 2010 | $1 M | No. 1 | Under $2 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Collegium Pharmaceutical, Inc., its revenue in fiscal 2025 came from these product and service lines: Belbuca $221.65 million (28%), Xtampza ER $199.31 million (26%), Jornay PM $148.86 million (19%), Nucynta IR $115.31 million (15%), Nucynta ER $80.98 million (10%).
Annual report (SEC XBRL) · Dec 2025
Collegium Pharmaceutical Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).
SEC Form D · Nov 2018
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2018
Products and services#
No products or services of Collegium Pharmaceutical Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| FHM VI, L.L.C. | Other | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| FHM VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Frazier Healthcare VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Longitude Capital Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Longitude Capital Partners, LLC | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Longitude Venture Partners L.P. | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Skyline Venture Management V, LLC | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Skyline Venture Partners V LP | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| TPG Group Holdings (SBS) Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 18 investors.
Largest shareholders today
Institutions holding Collegium Pharmaceutical, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$119 M17.53%
- Millennium Management LLC$52 M7.73%
- State Street Corp$39 M5.70%
- Principal Financial Group Inc$33 M4.87%
- Massachusetts Financial Services Co /ma/$32 M4.78%
- Renaissance Technologies LLC$31 M4.53%
- Vanguard Capital Management LLC$30 M4.43%
- Eventide Asset Management, LLC$30 M4.38%
- Woodline Partners LP$28 M4.20%
- Invesco Ltd.$28 M4.06%
- Geode Capital Management, LLC$20 M2.99%
- Dimensional Fund Advisors LP$20 M2.99%
- Victory Capital Management Inc$20 M2.97%
- J. Goldman & Co LP$18 M2.66%
- Vanguard Portfolio Management LLC$15 M2.28%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alison B. Fleming | Chief Technology Officer | Nov 2018 |
| Joseph Ciaffoni | President and Chief Executive Officer | Nov 2018 |
| Paul Brannelly | Executive Vice President and Chief Financial Officer | Nov 2018 |
| Scott B. Dreyer | Executive Vice President and Chief Commercial Officer | Nov 2018 |
| Shirley B. Kuhlmann | Executive Vice President and General Counsel | Nov 2018 |
| Michael Heffernan | Executive officer | Mar 2015 |
| Steven N. Tannenbaum | Executive officer | Mar 2010 |
| David Hirsch | Director | Nov 2018 |
| Garen Bohlin | Director | Nov 2018 |
| Gino Santini | Director | Nov 2018 |
| Gwen A Melincoff | Director | Nov 2018 |
| John A Fallon | Director | Nov 2018 |
| John Freund | Director | Nov 2018 |
| Joseph Ciaffoni | President and Chief Executive Officer | Nov 2018 |
| Michael Heffernan | Director | Nov 2018 |
| Theodore A Schroeder | Director | Nov 2018 |
| Eran Nadav | Director | Mar 2015 |
| Patrick Heron | Director | Mar 2015 |
| David W. Hirsch | Director | Oct 2013 |
| Gino W. Santini | Director | Oct 2013 |
| Robert W. Jevon | Director | Oct 2013 |
| Stephen W. Hoffman | Director | Oct 2013 |
| Patrick Fortune | Director | Feb 2012 |
| Stephen Hoffman | Director | Feb 2012 |
| Matthew N. Strobeck | Director | Mar 2010 |
| Patrick N. Fortune | Director | Mar 2010 |
| Patrick N. Heron | Director | Mar 2010 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.